Literature DB >> 26282541

Fibrin activates GPVI in human and mouse platelets.

Osama M Alshehri1, Craig E Hughes1, Samantha Montague1, Stephanie K Watson1, Jon Frampton1, Markus Bender2, Steve P Watson1.   

Abstract

The glycoprotein VI (GPVI)-Fc receptor γ (FcRγ) chain is the major platelet signaling receptor for collagen. Paradoxically, in a FeCl3 injury model, occlusion, but not initiation of thrombus formation, is delayed in GPVI-deficient and GPVI-depleted mice. In this study, we demonstrate that GPVI is a receptor for fibrin and speculate that this contributes to development of an occlusive thrombus. We observed a marked increase in tyrosine phosphorylation, including the FcRγ chain and Syk, in human and mouse platelets induced by thrombin in the presence of fibrinogen and the αIIbβ3 blocker eptifibatide. This was not seen in platelets stimulated by a protease activated receptor (PAR)-4 peptide, which is unable to generate fibrin from fibrinogen. The pattern of tyrosine phosphorylation was similar to that induced by activation of GPVI. Consistent with this, thrombin did not induce tyrosine phosphorylation of Syk and the FcRγ chain in GPVI-deficient mouse platelets. Mouse platelets underwent full spreading on fibrin but not fibrinogen, which was blocked in the presence of a Src kinase inhibitor or in the absence of GPVI. Spreading on fibrin was associated with phosphatidylserine exposure (procoagulant activity), and this too was blocked in GPVI-deficient platelets. The ectodomain of GPVI was shown to bind to immobilized monomeric and polymerized fibrin. A marked increase in embolization was seen following FeCl3 injury in GPVI-deficient mice, likely contributing to the delay in occlusion in this model. These results demonstrate that GPVI is a receptor for fibrin and provide evidence that this interaction contributes to thrombus growth and stability.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26282541      PMCID: PMC4582337          DOI: 10.1182/blood-2015-04-641654

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction.

Authors:  Peter Seizer; Oliver Borst; Harald F Langer; Andreas Bültmann; Götz Münch; Yared Herouy; Konstantinos Stellos; Björn Krämer; Boris Bigalke; Berthold Büchele; Max G Bachem; Dietmar Vestweber; Thomas Simmet; Meinrad Gawaz; Andreas E May
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

2.  Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl(3) -induced thrombosis.

Authors:  M Bender; I Hagedorn; B Nieswandt
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 3.  GPVI and CLEC-2 in hemostasis and vascular integrity.

Authors:  S P Watson; J M J Herbert; A Y Pollitt
Journal:  J Thromb Haemost       Date:  2010-03-25       Impact factor: 5.824

Review 4.  The future of glycoprotein VI as an antithrombotic target.

Authors:  M Zahid; P Mangin; S Loyau; B Hechler; P Billiald; C Gachet; M Jandrot-Perrus
Journal:  J Thromb Haemost       Date:  2012-12       Impact factor: 5.824

5.  Mechanisms underlying FeCl3-induced arterial thrombosis.

Authors:  A Eckly; B Hechler; M Freund; M Zerr; J-P Cazenave; F Lanza; P H Mangin; C Gachet
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

Review 6.  Platelet GPVI: a target for antithrombotic therapy?!

Authors:  Sebastian Dütting; Markus Bender; Bernhard Nieswandt
Journal:  Trends Pharmacol Sci       Date:  2012-08-15       Impact factor: 14.819

7.  Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice.

Authors:  Markus Bender; Frauke May; Viola Lorenz; Ina Thielmann; Ina Hagedorn; Brenda A Finney; Timo Vögtle; Katharina Remer; Attila Braun; Michael Bösl; Steve P Watson; Bernhard Nieswandt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-28       Impact factor: 8.311

8.  Platelet ITAM signaling is critical for vascular integrity in inflammation.

Authors:  Yacine Boulaftali; Paul R Hess; Todd M Getz; Agnieszka Cholka; Moritz Stolla; Nigel Mackman; A Phillip Owens; Jerry Ware; Mark L Kahn; Wolfgang Bergmeier
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

9.  Measuring soluble platelet glycoprotein VI in human plasma by ELISA.

Authors:  Mohammad Al-Tamimi; Fi-Tjen Mu; Masaaki Moroi; Elizabeth E Gardiner; Michael C Berndt; Robert K Andrews
Journal:  Platelets       Date:  2009-05       Impact factor: 3.862

10.  A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder.

Authors:  C Hermans; C Wittevrongel; C Thys; P A Smethurst; C Van Geet; K Freson
Journal:  J Thromb Haemost       Date:  2009-06-22       Impact factor: 5.824

View more
  64 in total

1.  TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Authors:  S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

2.  Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Authors:  Phillip L R Nicolson; Craig E Hughes; Stephanie Watson; Sophie H Nock; Alexander T Hardy; Callum N Watson; Samantha J Montague; Hayley Clifford; Aarnoud P Huissoon; Jean-Daniel Malcor; Mark R Thomas; Alice Y Pollitt; Michael G Tomlinson; Guy Pratt; Steve P Watson
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

3.  Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects.

Authors:  Constance C F M J Baaten; Frauke Swieringa; Tomasz Misztal; Tom G Mastenbroek; Marion A H Feijge; Paul E Bock; Marjo M P C Donners; Peter W Collins; Renhao Li; Paola E J van der Meijden; Johan W M Heemskerk
Journal:  Blood Adv       Date:  2018-09-25

4.  Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI.

Authors:  Samantha J Montague; Céline Delierneux; Christelle Lecut; Nathalie Layios; Robert J Dinsdale; Christine S-M Lee; Natalie S Poulter; Robert K Andrews; Peter Hampson; Christopher M Wearn; Nathalie Maes; Jonathan Bishop; Amy Bamford; Chris Gardiner; Woei Ming Lee; Tariq Iqbal; Naiem Moiemen; Steve P Watson; Cécile Oury; Paul Harrison; Elizabeth E Gardiner
Journal:  Blood Adv       Date:  2018-02-13

5.  Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activation.

Authors:  Joanne L Dunster; Amanda J Unsworth; Alexander P Bye; Elizabeth J Haining; Marcin A Sowa; Ying Di; Tanya Sage; Chiara Pallini; Jeremy A Pike; Alexander T Hardy; Bernhard Nieswandt; Ángel García; Steve P Watson; Natalie S Poulter; Jonathan M Gibbins; Alice Y Pollitt
Journal:  J Thromb Haemost       Date:  2019-12-06       Impact factor: 5.824

Review 6.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

7.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

8.  Src family kinases inhibition by dasatinib blocks initial and subsequent platelet deposition on collagen under flow, but lacks efficacy with thrombin generation.

Authors:  Yiyuan Zhang; Scott L Diamond
Journal:  Thromb Res       Date:  2020-05-13       Impact factor: 3.944

9.  Modeling Venous Thrombosis In Vitro: More Than Just (Valve) Pocket Change.

Authors:  Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05       Impact factor: 8.311

10.  Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy.

Authors:  M Y Lee; C C Verni; B A Herbig; S L Diamond
Journal:  J Thromb Haemost       Date:  2017-10-27       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.